WHO ICTRP trial
Window of opportunity trial of durvalumab (MEDI4736) to identify immune dynamics…
KCT0006973 · Clinical Research Information Service (CRIS) · Not Recruiting
Key facts
| Trial ID | KCT0006973 |
|---|---|
| Public title | Window of opportunity trial of durvalumab (MEDI4736) to identify immune dynamics in operable non-small cell lung cancer (NSCLC) (MIRACLE) |
| Scientific title | Window of opportunity trial of durvalumab (MEDI4736) to identify immune dynamics in operable non-small cell lung cancer (NSCLC) (MIRACLE) |
| Primary sponsor | Yonsei University Health System, Severance Hospital |
| Registry | Clinical Research Information Service (CRIS) |
| Recruitment status | Not Recruiting |
| Study type | Interventional Study |
| Phase | Phase2 |
| Countries | Korea, Republic of |
| Conditions | Neoplasms |
| Interventions | Drug : If the subject has enrolled, the drugs will be administered until PD as below. - durvalumab 1500 mg QD* - Surgery within 1 to 8 weeks - 4 cycles of durvalumab 1500 mg/m2 (Day 1, Day 8)+cisplatin 80 mg/m2 (Day 1) q3wks -durvalumab… |
| Registration date | Feb 3, 2022 |
| Target size | 25 |
| Registry page | cris.nih.go.kr |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: